Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia

Journal of Clinical Investigation

Volumn 121, Issue 6, 2011, Pages 2361-2370

  Aucagne, Romain ^a   Droin, Nathalie ^b   Paggetti, Jérôme ^a,f   Lagrange, Brice ^a   Largeot, Anne ^a   Hammann, Arlette ^a,c   Bataille, Amandine ^a,c   Martin, Laurent ^c   Yan, Kai Ping ^d,g   Fenaux, Pierre ^e   Losson, Régine ^d   Solary, Eric ^b   Bastie, Jean Noël ^a,c   Delva, Laurent ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b INSERM   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^g WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G7; TRANSCRIPTION FACTOR; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CELL COMPARTMENTALIZATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG EFFICACY; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LOSS OF FUNCTION MUTATION; MONOCYTE; MOUSE; MULTIPLE CYCLE TREATMENT; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION; STEM CELL EXPANSION; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; AGING; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; CELL DIFFERENTIATION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, TUMOR SUPPRESSOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSCRIPTION FACTORS;

EID: 79957917231     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45213     Document Type: Article

References (58)

1. Venturini L, et al. TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene. 1999;18(5):1209-1217. (Pubitemid 29085994)
2. Beckstead R, et al. Bonus, a Drosophila homolog of TIF1 proteins, interacts with nuclear receptors and can inhibit betaFTZ-F1-dependent transcription. Mol Cell. 2001;7(4):753-765. (Pubitemid 32436436)
3. Friedman JR, et al. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev. 1996;10(16):2067-2078. (Pubitemid 26346114)
4. Khetchoumian K, et al. TIF1delta, a novel HP1-interacting member of the transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids. J Biol Chem. 2004;279(46):48329-48341. (Pubitemid 39540989)
5. Le Douarin B, et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 1995;14(9):2020-2033.
6. Moosmann P, Georgiev O, Le Douarin B, Bourquin JP, Schaffner W. Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res. 1996;24(24):4859-4867. (Pubitemid 27007888)
7. Zhong S, et al. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet. 1999;23(3):287-295. (Pubitemid 29526425)
8. Khetchoumian K, et al. Loss of Trim24 (Tif1- alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet. 2007; 39(12):1500-1506. (Pubitemid 350191338)
9. Underhill C, Qutob MS, Yee SP, Torchia J. A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1. J Biol Chem. 2000; 275(51):40463-40470. (Pubitemid 32064681)
10. Abrink M, et al. Conserved interaction between distinct Kruppel-associated box domains and the transcriptional intermediary factor 1 beta. Proc Natl Acad Sci U S A. 2001;98(4):1422-1426. (Pubitemid 32165514)
11. Cammas F, Mark M, Dolle P, Dierich A, Chambon P, Losson R. Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development. Development. 2000;127(13):2955-2963. (Pubitemid 30487613)
12. Ransom DG, et al. The zebrafish moonshine gene encodes transcriptional intermediary factor 1gamma, an essential regulator of hematopoiesis. PLoS Biol. 2004;2(8):E237.
13. Kim J, Kaartinen V. Generation of mice with a conditional allele for Trim33. Genesis. 2008;46(6):329-333. (Pubitemid 352008882)
14. Morsut L, et al. Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development. 2010;137(15):2571-2578.
15. Bai X, et al. TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell. 2010; 142(1):133-143.
16. Dupont S, et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell. 2005;121(1):87-99.
17. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006;125(5):929-941. (Pubitemid 43795187)
18. Dupont S, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell. 2009; 136(1):123-135.
19. Doisne JM, et al. iNKT cell development is orchestrated by different branches of TGF-beta signaling. J Exp Med. 2009;206(6):1365-1378.
20. Keller P, et al. FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow. J Exp Med. 2001; 194(5):581-589. (Pubitemid 32844769)
21. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005; 121(7):1109-1121. (Pubitemid 40884400)
22. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8(12):970-982. (Pubitemid 350174642)
23. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993; 92(6):2569-2576. (Pubitemid 24006519)
24. Biswas S, et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest. 2007;117(5):1305-1313. (Pubitemid 46718418)
25. Karlic R, Chung HR, Lasserre J, Vlahovicek K, Vingron M. Histone modification levels are predictive for gene expression. Proc Natl Acad Sci U S A. 2010; 107(7):2926-2931.
26. Kantarjian H, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57. (Pubitemid 46053042)
27. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia. 2008; 22(7):1335-1342.
28. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004;119(3):431-443. (Pubitemid 39423844)
29. Walkley CR, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell. 2007;129(6):1097-1110. (Pubitemid 46908696)
30. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 2007;129(6):1081-1095. (Pubitemid 46908695)
31. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. (Pubitemid 36724933)
32. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell. 2010; 6(3):265-278.
33. Langer JC, Henckaerts E, Orenstein J, Snoeck HW. Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function. J Exp Med. 2004;199(1):5-14. (Pubitemid 38076473)
34. Capron C, et al. A major role of TGF-beta1 in the homing capacities of murine hematopoietic stem cell/progenitors. Blood. 2010;116(8):1244-1253.
35. Kosmider O, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676-1681.
36. Gelsi-Boyer V, et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008;8:299.
37. Kuo MC, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009; 23(8):1426-1431.
38. Gelsi-Boyer V, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800.
39. Tyner JW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2009;113(8):1749-1755.
40. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77(2):307-316. (Pubitemid 24138627)
41. Steensma DP, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207-1209.
42. Jelinek J, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106(10):3370-3373.
43. Lee BH, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007;12(4):367-380. (Pubitemid 47554548)
44. Jankowska A, et al. Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2. ASH Annual Meeting 2010. December 6, 2010. Orlando, Florida, USA.
45. Szpurka H, et al. UTX Mutations and Epigenetic Changes In MDS/MPN and Related Myeloid Malignancies. ASH Annual Meeting 2010. December 5, 2010. Orlando, Florida, USA.
46. Grossmann V, et al. Analyses of 81 chronic myelomonocytic leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 revealed mutations in 86.4% of all patients with TET2 and EZH2 being of high prognostic relevance. ASH Annual Meeting 2010. December 6, 2010. Orlando, Florida, USA.
47. Kosmider O, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094-1096.
48. Dunbar AJ, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68(24):10349-10357.
49. Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
50. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
51. Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843.
52. Smith AE, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116(19):3923-3932.
53. Kohlmann A, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010; 28(24):3858-3865.
54. Vincent DF, et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet. 2009;5(7):e1000575.
55. Candelaria M, et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial [published online ahead of print October 5, 2010]. Ann Hematol. doi:10.1007/s00277-010-1090-2.
56. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 2000;24(1):88-91. (Pubitemid 30041428)
57. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705. (Pubitemid 46273577)
58. Paggetti J, et al. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene. 2010;29(36):5019-5031.